Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Opinion|Articles|July 4, 2025
Top 10 Urology Times videos from the first half of 2025
Author(s)Urology Times staff
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Catch up on exclusive videos you may have missed from the first half of the year.
Advertisement
Advertisement
The first half of 2025 generated plenty of headlines in the urology space, ranging from conferences such as the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, American Urological Association 2025 Annual Meeting, and ASCO Annual Meeting. Besides conferences, other key headlines involved the FDA’s approval of perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Advertisement
Advertisement